Effect of target cell availability on HIV-1 production in vitro

AIDS

Volumn 16, Issue 3, 2002, Pages 341-345

  Schwartz, Elissa J ^a   Neumann, Avidan U ^a   Teixeira, Avelino V ^a   Bruggeman, Leslie A ^a   Rappaport, Jay ^a   Perelson, Alan S ^a   Klotman, Paul E ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Antiretroviral therapy; Mathematical models; Target cell availability; Viral escape; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; GAG PROTEIN; POL PROTEIN; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TARGET CELL; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0037083786     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200202150-00004     Document Type: Article

References (25)

1. Anti-CD4 therapy for AIDS suggested by mathematical models
2. T-cell activation: A cellular target for antiretroviral therapy
3. Taking aim at HIV replication
4. Residual HIV-1 disease in the era of highly active antiretroviral therapy
5. Cyclosporin A in combination with HAART in primary HIV-1 infection
6. Hydroxyurea and HIV: 5 Years later - From antiviral to immune-modulating effects
7. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters
8. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug
9. Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine
10. Hydroxyurea interferes with antigen-dependent T-cell activation in vitro
11. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo
12. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity
13. Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1
14. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine
15. Population dynamics of HIV within an individual after treatment with zidovudine
16. Zidovudine and HIV: Mathematical models of within-host population dynamics
17. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time
18. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads
19. Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model
20. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine
21. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy
22. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: A randomized, double-blind, placebo-controlled trial
23. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs
24. Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine
25. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients